Literature DB >> 25332977

THERANOSTICS-clinical aimshots in surgical warfare against well-differentiated neuroendocrine neoplasms.

Dieter Hörsch1, Harshad R Kulkarni1, Richard P Baum1.   

Abstract

Targeted, personalized or molecular medicine all imply maximal treatment with minimal side effects and requires definition and detection of molecular targets prior to therapy. THERANOSTICS in nuclear medicine utilizes the same vector with distinct radionuclides for diagnosis and treatment and has become innovative standard for the treatment of somatostatin receptor expressing neuroendocrine neoplasms.

Entities:  

Keywords:  Molecular medicine; neuroendocrine neoplasms; peptide receptor radionuclide therapy; personalized medicine

Year:  2014        PMID： 25332977      PMCID： PMC4200649          DOI： 10.3978/j.issn.2305-5839.2013.07.03

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


  14 in total

Review 1.  Current treatment options for neuroendocrine tumors.

Authors:  D Hörsch; P Grabowski; C P Schneider; A Petrovitch; D Kaemmerer; M Hommann; R P Baum
Journal:  Drugs Today (Barc)       Date:  2011-10       Impact factor: 2.245

2.  Paul Ehrlich--in search of the magic bullet.

Authors:  Florian Winau; Otto Westphal; Rolf Winau
Journal:  Microbes Infect       Date:  2004-07       Impact factor: 2.700

Review 3.  Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.

Authors:  Jaap J M Teunissen; Dik J Kwekkeboom; R Valkema; Eric P Krenning
Journal:  Endocr Relat Cancer       Date:  2011-10-17       Impact factor: 5.678

Review 4.  Role of PET/CT in the functional imaging of endocrine pancreatic tumors.

Authors:  Vittoria Rufini; Richard P Baum; Paola Castaldi; Giorgio Treglia; Anna Maria De Gaetano; Cecilia Carreras; Daniel Kaemmerer; Merten Hommann; Dieter Hörsch; Lorenzo Bonomo; Alessandro Giordano
Journal:  Abdom Imaging       Date:  2012-12

5.  Yttrium-90 DOTATOC: first clinical results.

Authors:  A Otte; R Herrmann; A Heppeler; M Behe; E Jermann; P Powell; H R Maecke; J Muller
Journal:  Eur J Nucl Med       Date:  1999-11

6.  Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

Authors:  Christian Waldherr; Miklos Pless; Helmut R Maecke; Tilmann Schumacher; Armin Crazzolara; Egbert U Nitzsche; Andreas Haldemann; Jan Mueller-Brand
Journal:  J Nucl Med       Date:  2002-05       Impact factor: 10.057

7.  90Y-edotreotide for metastatic carcinoid refractory to octreotide.

Authors:  David L Bushnell; Thomas M O'Dorisio; M Sue O'Dorisio; Yusuf Menda; Rodney J Hicks; Eric Van Cutsem; Jean-Louis Baulieu; Francoise Borson-Chazot; Lowell Anthony; Al B Benson; Kjell Oberg; Ashley B Grossman; Mary Connolly; Hakim Bouterfa; Yong Li; Katherine A Kacena; Norman LaFrance; Stanislas A Pauwels
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

8.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

Authors:  Dik J Kwekkeboom; Wouter W de Herder; Boen L Kam; Casper H van Eijck; Martijn van Essen; Peter P Kooij; Richard A Feelders; Maarten O van Aken; Eric P Krenning
Journal:  J Clin Oncol       Date:  2008-05-01       Impact factor: 44.544

9.  Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.

Authors:  Roelf Valkema; Stanislas Pauwels; Larry K Kvols; Raffaella Barone; Francois Jamar; Willem H Bakker; Dik J Kwekkeboom; Hakim Bouterfa; Eric P Krenning
Journal:  Semin Nucl Med       Date:  2006-04       Impact factor: 4.446

10.  Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.

Authors:  D J Kwekkeboom; W H Bakker; B L Kam; J J M Teunissen; P P M Kooij; W W de Herder; R A Feelders; C H J van Eijck; M de Jong; A Srinivasan; J L Erion; E P Krenning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-09       Impact factor: 9.236
View more
  3 in total

1.  Role of (68)Ga somatostatin receptor PET/CT in the detection of endogenous hyperinsulinaemic focus: an explorative study.

Authors:  Vikas Prasad; Aurora Sainz-Esteban; Ruza Arsenic; Ursula Plöckinger; Timm Denecke; Ulrich-Frank Pape; Andreas Pascher; Peter Kühnen; Marianne Pavel; Oliver Blankenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-29       Impact factor: 9.236

Review 2.  Theranostics of Neuroendocrine Tumors.

Authors:  Sze Ting Lee; Harshad R Kulkarni; Aviral Singh; Richard P Baum
Journal:  Visc Med       Date:  2017-10-20

3.  Role of Staging in Patients with Small Intestinal Neuroendocrine Tumours.

Authors:  Ashley Kieran Clift; Omar Faiz; Adil Al-Nahhas; Andreas Bockisch; Marc Olaf Liedke; Erik Schloericke; Harpreet Wasan; John Martin; Paul Ziprin; Krishna Moorthy; Andrea Frilling
Journal:  J Gastrointest Surg       Date:  2015-09-22       Impact factor: 3.452
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.